Use of Clinical Notes to Assess Neuropsychiatric Events After Montelukast Initiation Read more about Use of Clinical Notes to Assess Neuropsychiatric Events After Montelukast Initiation
Assessing Treatment Effects in Observational Data With Missing Confounders: A Comparative Study of Practical Doubly-Robust and Traditional Missing Data Methods Read more about Assessing Treatment Effects in Observational Data With Missing Confounders: A Comparative Study of Practical Doubly-Robust and Traditional Missing Data Methods
Duration of Follow Up for New Molecular Entities Approved in 2021: Second Descriptive Analysis Read more about Duration of Follow Up for New Molecular Entities Approved in 2021: Second Descriptive Analysis
Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis" Read more about Intentional Self-Harm Algorithm Defined in "Intentional Self-Harm Following Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RA) Use in Patients with Diabetes, By Age and Sex Subgroups: An Inverse Probability of Treatment Weighting Analysis"
Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis Read more about Intentional Self-Harm Following Glucagon-Like Peptide 1 (GLP-1) Receptor Agonists Use in Patients 18 Years and Older: A Descriptive Analysis
Intentional Self-Harm Following Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) Use in Patients with Diabetes & Obesity: A Descriptive Analysis Read more about Intentional Self-Harm Following Glucagon-Like Peptide 1 Receptor Agonists (GLP-1RA) Use in Patients with Diabetes & Obesity: A Descriptive Analysis
FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications Read more about FDA Requests Removal of Suicidal Behavior and Ideation Warning from Glucagon-Like Peptide-1 Receptor Agonist (GLP-1 RA) Medications